Such that, the secretion of inflammatory cytokines, such as tumor necrosis factor- (TNF), would lead to neuroinflammation and migraine episodes by increasing the cellular permeability and interactions (11, 12)
the FDA itself hasn't formally loosened restrictions yet. The vote came from the PCAC, not the FDA, and their recommendation is strictly advisory, not legally binding. According to Holt, nothing changes for consumers right now simply because the PCACs vote is an advisory one
2006 Sep-Oct;8(9-10):1865-79
Expanded approvals : Trials are ongoing for fatty liver disease, cardiovascular prevention in non-diabetics, and neurodegenerative disorders
Ovarian damage from chemotherapy and current approaches to its protection